Biotech company Atrium Therapeutics Inc (Nasdaq:RNA) announced on Tuesday that it has awarded inducement grants to one non-executive individual newly hired by the company, under its 2026 Employment Inducement Incentive Award Plan.

The employee received, in the aggregate, non-qualified stock options to purchase 9,500 shares of Atrium Therapeutics' common stock, par value USD0.001 per share, with an exercise price of USD7.98 per share, the closing price of the company's common stock on the effective date of the grant, 25% of which will vest and become exercisable on the first anniversary of the grant date. The remaining underlying shares will vest in 36 substantially equal instalments each month thereafter, subject to the employee's continued service with the company through each applicable vesting date. The employee was also awarded restricted stock units for an aggregate of 4,750 shares of the company's common stock, 25% of which will vest on the first anniversary of the grant date, and the remaining underlying shares will vest in three substantially equal instalments each year thereafter, subject to continued service with the company through each applicable vesting date.

These awards were approved by the Human Capital Management Committee of the company's board of directors, which is comprised solely of independent directors, in accordance with Nasdaq Listing Rule 5635(c)(4).